199 related articles for article (PubMed ID: 25003557)
1. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.
Drusano GL; Neely M; Van Guilder M; Schumitzky A; Brown D; Fikes S; Peloquin C; Louie A
PLoS One; 2014; 9(7):e101311. PubMed ID: 25003557
[TBL] [Abstract][Full Text] [Related]
2. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
[TBL] [Abstract][Full Text] [Related]
3. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
[TBL] [Abstract][Full Text] [Related]
4. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A
mBio; 2010 Aug; 1(3):. PubMed ID: 20802826
[TBL] [Abstract][Full Text] [Related]
5. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
[TBL] [Abstract][Full Text] [Related]
6. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
[TBL] [Abstract][Full Text] [Related]
7. Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an
de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866874
[TBL] [Abstract][Full Text] [Related]
8. Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.
Gumbo T; Sherman CM; Deshpande D; Alffenaar JW; Srivastava S
Int J Infect Dis; 2021 Mar; 104():680-684. PubMed ID: 33556616
[TBL] [Abstract][Full Text] [Related]
9. Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.
Drusano GL; Myrick J; Maynard M; Nole J; Duncanson B; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Louie A
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866864
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
Brown AN; Drusano GL; Adams JR; Rodriquez JL; Jambunathan K; Baluya DL; Brown DL; Kwara A; Mirsalis JC; Hafner R; Louie A
mBio; 2015 Nov; 6(6):e01741-15. PubMed ID: 26530386
[TBL] [Abstract][Full Text] [Related]
11. Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.
Heinrichs MT; Drusano GL; Brown DL; Maynard MS; Sy SKB; Rand KH; Peloquin CA; Louie A; Derendorf H
Int J Antimicrob Agents; 2019 Mar; 53(3):275-283. PubMed ID: 30385322
[TBL] [Abstract][Full Text] [Related]
12. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
[TBL] [Abstract][Full Text] [Related]
13. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
Williams KN; Stover CK; Zhu T; Tasneen R; Tyagi S; Grosset JH; Nuermberger E
Antimicrob Agents Chemother; 2009 Apr; 53(4):1314-9. PubMed ID: 19075058
[TBL] [Abstract][Full Text] [Related]
14. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
[TBL] [Abstract][Full Text] [Related]
15. Assessment and modelling of antibacterial combination regimens.
Rao GG; Li J; Garonzik SM; Nation RL; Forrest A
Clin Microbiol Infect; 2018 Jul; 24(7):689-696. PubMed ID: 29269090
[TBL] [Abstract][Full Text] [Related]
16. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Coban AY; Bilgin K; Uzun M; Durupinar B
Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
[TBL] [Abstract][Full Text] [Related]
17. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.
Srivastava S; Pasipanodya JG; Meek C; Leff R; Gumbo T
J Infect Dis; 2011 Dec; 204(12):1951-9. PubMed ID: 22021624
[TBL] [Abstract][Full Text] [Related]
18. A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.
Srivastava S; Deshpande D; Pasipanodya JG; Thomas T; Swaminathan S; Nuermberger E; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S75-S79. PubMed ID: 27742637
[TBL] [Abstract][Full Text] [Related]
19. Does linezolid have a role in shortening treatment of tuberculosis?
Yew WW; Chan DP; Chang KC
Clin Microbiol Infect; 2019 Sep; 25(9):1060-1062. PubMed ID: 31238119
[No Abstract] [Full Text] [Related]
20. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
